# To Evaluate the Efficacy (Immunogenicity) and Safety of Euvichol in Healthy Adults and Children

> **NCT02164110** · PHASE3 · COMPLETED · sponsor: **EuBiologics Co.,Ltd** · enrollment: 3632 (actual)

## Conditions studied

- Prevention Harmful Effects

## Interventions

- **BIOLOGICAL:** Euvichol
- **BIOLOGICAL:** Shanchol

## Key facts

- **NCT ID:** NCT02164110
- **Lead sponsor:** EuBiologics Co.,Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-05
- **Primary completion:** 2014-09
- **Final completion:** 2014-10
- **Target enrollment:** 3632 (ACTUAL)
- **Last updated:** 2014-12-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02164110

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02164110, "To Evaluate the Efficacy (Immunogenicity) and Safety of Euvichol in Healthy Adults and Children". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02164110. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*